PTC Therapeutics (PTCT) said Monday that a phase 2 study of PTC518, or votoplam, in stage 2 and 3 Huntington's disease met its primary endpoint of reduction in blood Huntingtin protein levels at week 12.
The company said the study showed dose-dependent lowering of blood Huntingtin levels, with 23% at the 5mg dose for both stage 2 and stage 3 patients. Treatment may differ at the 10mg dose level based on the study results, according to the company.
Votoplam also demonstrated a favorable safety and tolerability profile across all dose levels and disease stages, PTC Therapeutics added.
Shares of PTC Therapeutics were down nearly 16% in recent premarket activity Monday.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.